Skip to content

Effect of Ayurvedic treatment in COPD

A Comparative study to Evaluate Efficacy of "Shwasa Kuthar Rasa" and "Pippali Vardhman Rasayan" in the management of Chronic Obstructive Pulmonary Disease(Praanavaha Sroto Dushti) - COPD

Status
Active, not recruiting
Phases
Phase 3
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2018/02/011918
Enrollment
30
Registered
2018-02-15
Start date
Unknown
Completion date
Unknown
Last updated
2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: null- Patients of COPD

Interventions

Intervention1: Pippali Vardhman Rasayan: Starting from 6 pippali from first day each day 6 pippali will be added till the 13th day . From 14th day 6 pippali will be consumed in a study of 25 days oral

Sponsors

Ch Brahm Prakash Ayurved Charak Sansthan
Lead Sponsor
Department of Kayachikitsa
Collaborator

Eligibility

Inclusion criteria

Inclusion criteria: 1. Age Group between 35-65 years. 2. Patients of Both Sexes. 3. Smoking history current or former active ciggarette smokers or history of occupational exposure to COPD. 4.Patients present with signs and symptoms of COPD. 5.Radiographic evidence suggestive of COPD. 6.Spiro-metric diagnosis of COPD(as per GOLD criteria) 7. The patients who are ready to sign informed consent form to participate in study. 8. The patients who are ready to be consistent in visits during whole trial period. 9. Firm home address and contact number which is readily accessible during whole course of trial.

Exclusion criteria

Exclusion criteria: 1) Seriously ill and morbid patients which are unlikely to survive for next 6 months. 2) Pregnant and lactating women 3) Patient with alcohol dependence 4) History of hypersensitivity to any of trial drug 5) Patient with serious hepatic disorder, renal disorder, diabetes mellitus or any condition that may jeopardize the study 6) Patient with any other concomitant respiratory disorder 7) Patient with co-morbid disorders(Diabetes Mellitus, Pulmonary Tuberculosis ,Rheumatoid Arthritis , Carcinoma) 8) Patient with poorly controlled hypertension (systolic >160 mmHg and diastolic > 100 mmHg) 9) Patient receiving mast cell stabilizers, anti-depressants, anticholinergics etc. or any other drugs that may have an influence on the outcome of the study.

Design outcomes

Primary

MeasureTime frame
1) Improvement in BODE index(Body mass index, Obstruction, Dyspnoea, Exercise endurance) score 2) Improvement in SGRQ(St. Georgeâ??s Respiratory Questionnaire) score 3) Improvement in severity of clinical symptoms of Praanavaha Sroto Dushti. Timepoint: Every 7 days

Secondary

MeasureTime frame
1) Improvement in Forced Expiratory Volume in 1 second (FEV1) pre and post bronchodilator intake. 2) Improvement in FEV1/FVC ratio pre and post bronchodilator intake 3) Reduction in episodes of cough 4) Reduction in volume of sputum produced 5) Percentage of patients who acquired lakshanas of karyaphala described in Charaksamhita. Timepoint: Every 7 days

Countries

India

Contacts

Public ContactNeha Garg

Ch. Brahm Prakash Ayurved Charak Sansthan, Khera Dabar Najafgarh, New Delhi

dryogeshpandey@gmail.com9013858523

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026